Last reviewed · How we verify
NCT07036978
Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer
trial testing Collecting biospecimens in Pancreatic Ductal Adenocarcinoma (PDAC) in 140 participants. Not yet recruiting.
31 July 2028
Quick facts
| Lead sponsor | Chang Gung Memorial Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 140 |
| Start date | 1 May 2026 |
| Primary completion | 31 July 2028 |
| Estimated completion | 31 July 2033 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Collecting biospecimens
Conditions studied
- Pancreatic Ductal Adenocarcinoma (PDAC) — all drugs for Pancreatic Ductal Adenocarcinoma (PDAC) →
Sponsor
Chang Gung Memorial Hospital
Who can join
18 and older, any sex, with Pancreatic Ductal Adenocarcinoma (PDAC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Brief Summary The goal of this observational study is to identify biomarkers and develop a personalised treatment stratification model for patients with unresectable pancreatic ductal adenocarcinoma (PDAC) in Taiwan. The main questions it aims to answer are: * What serum metabolomic profiles predict treatment response and patient survival? * How do immune response markers and gut microbiome composition correlate with therapeutic outcomes? * Can a combined multi-omic stratification algorithm enhance personalised therapy planning? Participants, who have been diagnosed with unresectable locally advanced or metastatic PDAC and are undergoing systemic therapy and chemoradiotherapy, will: * Provide serum samples for comprehensive metabolomic profiling via high-performance liquid chromatography-mass spectrometry. * Undergo immune profiling through flow cytometry. * Provide stool samples for gut microbiome analysis using 16S rRNA sequencing. * Be followed longitudinally to correlate these multi-omic findings with clinical outcomes. Researchers anticipate that integrating these multi-omic analyses will facilitate personalised therapy approaches, potentially improving patient outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Microbiota and Pancreatic Cancer: New Therapeutic Frontiers Between Engineered Microbes, Metabolites and Non-Bacterial Components.
De Lucia SS, Nista EC, Candelli M, Archilei S, et al · · 2025 · cited 1× · PMID 41300985 · DOI 10.3390/cancers17223618
Verify or expand the search:
- PubMed search for NCT07036978
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Collecting biospecimens
Trials testing the same drug.
- NCT06831669 — Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer · recruiting
Other recruiting trials for Pancreatic Ductal Adenocarcinoma (PDAC)
Currently open trials in the same condition.
- NCT07480928 — Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma · Phase 1, PHASE2 · recruiting
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07030283 — Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis · Phase 1 · recruiting
- NCT07235202 — A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarci · Phase 1, PHASE2 · recruiting
- NCT07217717 — Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 3 · recruiting
Other Chang Gung Memorial Hospital trials
Trials by the same sponsor.
- NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
- NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
- NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
- NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting
- NCT07472881 — Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07036978 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07036978.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing